Less Ads, More Data, More Tools Register for FREE

Pin to quick picksQinetiq Regulatory News (QQ.)

Share Price Information for Qinetiq (QQ.)

Share Price is delayed by 15 minutes
Get Live Data
483.80    3.20 (0.67%)
Bid:
483.60
Ask:
484.20
Spread: 0.60 (0.124%)
Market Cap: £2.49b
QQ. Live PriceLast checked at - London Stock Exchange

Intraday Qinetiq Share Chart

US robotics contract update

14 Mar 2019 13:06

RNS Number : 9169S
QinetiQ Group plc
14 March 2019
 

US robotics contract update

14 March 2019

QinetiQ Group plc (QinetiQ or the Group) notes the commentary in the press about its contract win for the Common Robotic System-Individual (CRS-I) program for the United States Army and confirms that it has been successful in this regard.

 

QinetiQ will release a fuller statement once customer formalities have been concluded, including details of the phasing of the Indefinite Delivery, Indefinite Quantity (IDIQ) contract terms, the results of which are not anticipated to have a material impact on Group expectations in the near term.

 

For further information please contact:

David Bishop, Group Director Investor Relations and Communications:

+44 (0) 7920 108675

Ian Brown, Group Head of Investor Relations:

+44 (0) 7908 251123

Jon Hay-Campbell, Group Head of Communications:

+44 (0) 7500 856953

 

 

About QinetiQ:

 

QinetiQ (QQ.L) is a leading science and engineering company operating primarily in the defence, security and critical infrastructure markets. We work in partnership with our customers to solve real world problems through innovative solutions delivering operational and competitive advantage. Visit our website www.QinetiQ.com. Follow us on LinkedIn and Twitter @QinetiQ. Visit our blog www.QinetiQ-blogs.com.

Disclaimer

This document contains certain forward-looking statements relating to the business, strategy, financial performance and results of the Company and/or the industry in which it operates. Actual results, levels of activity, performance, achievements and events are most likely to vary materially from those implied by the forward-looking statements. The forward-looking statements concern future circumstances and results and other statements that are not historical facts, sometimes identified by the words 'believes',' expects', 'predicts', 'intends', 'projects', 'plans', 'estimates', 'aims', 'foresees', 'anticipates', 'targets', 'goals', 'due', 'could', 'may', 'should', 'potential', 'likely' and similar expressions, although these words are not the exclusive means of doing so. These forward-looking statements include, without limitation, statements regarding the Company's future financial position, income growth, impairment charges, business strategy, projected levels of growth in the relevant markets, projected costs, estimates of capital expenditures, and plans and objectives for future operations. Forward-looking statements contained in this announcement regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. Nothing in this document should be regarded as a profit forecast.

The forward-looking statements, including assumptions, opinions and views of the Company or cited from third party sources, contained in this announcement are solely opinions and forecasts which are uncertain and subject to risks. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurance that these expectations will prove to be correct. Actual results may differ materially from those expressed or implied by these forward-looking statements. A number of factors could cause actual events to differ significantly and these are set out in the principal risks and uncertainties section of this document. Most of these factors are difficult to predict accurately and are generally beyond the control of the Company. Any forward-looking statements made by, or on behalf of, the Company speak only as of the date they are made. Save as required by law, the Company will not publicly release the results of any revisions to any forward-looking statements in this document that may occur due to any change in the Directors' expectations or to reflect events or circumstances after the date of this document.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
CNTLLFIVVLISLIA
Date   Source Headline
17th Oct 20238:00 amRNSDirector Declaration
11th Oct 20237:00 amRNSSecond Quarter Trading Update
10th Oct 20233:56 pmRNSDirector/PDMR Shareholding
4th Oct 20237:00 amRNS$127m contract win in the US (formerly Avantus)
3rd Oct 20237:00 amRNS$84m contract win in the US
28th Sep 20233:24 pmRNSDirector/PDMR Shareholding
12th Sep 20235:54 pmRNSDirector/PDMR Shareholding
31st Aug 20235:03 pmRNS$224m contract win in the US (formerly Avantus)
25th Aug 20232:23 pmRNSDirector/PDMR Shareholding
10th Aug 20234:31 pmRNSDirector/PDMR Shareholding
27th Jul 20234:45 pmRNSDirector/PDMR Shareholding
20th Jul 20232:00 pmRNSResult of AGM
20th Jul 20237:00 amRNSFirst Quarter Trading Update
11th Jul 20235:30 pmRNSDirector/PDMR Shareholding
21st Jun 202312:15 pmRNSDirector/PDMR Shareholding
14th Jun 202310:00 amRNSHolding(s) in Company
12th Jun 20234:00 pmRNSDirector/PDMR Shareholding
12th Jun 20232:00 pmRNSAnnual Financial Report
25th May 20237:00 amRNSResults for the year ended 31 March 2023
10th May 20234:55 pmRNSDirector/PDMR Shareholding
17th Apr 20237:00 amRNSFourth Quarter Trading Update
12th Apr 202311:35 amRNSDirector/PDMR Shareholding
5th Apr 20237:00 amRNSQinetiQ announces £259 million renewal of MSCA
30th Mar 20237:00 amRNSQinetiQ Awarded $92.6M Contract
23rd Mar 20235:00 pmRNSDirectorate Change
20th Mar 202310:30 amRNSDirector Declaration
15th Mar 20232:40 pmRNSDirector Declaration
10th Mar 20232:56 pmRNSDirector/PDMR Shareholding
17th Feb 20239:00 amRNSHolding(s) in Company
16th Feb 20237:00 amRNSGary Stewart appointed CEO for Australia Sector
10th Feb 20231:14 pmRNSDirector/PDMR Shareholding
6th Feb 20231:44 pmRNSDirector/PDMR Shareholding
18th Jan 20237:00 amRNSThird Quarter Trading Update
16th Jan 20237:00 amRNS£80m contract win with UK MOD
10th Jan 20233:43 pmRNSDirector/PDMR Shareholding
5th Jan 20232:38 pmRNSDirector Declaration
12th Dec 20225:23 pmRNSDirectorate Change
12th Dec 20221:44 pmRNSDirector/PDMR Shareholding
6th Dec 20227:00 amRNSCompletion of the acquisition of Air Affairs
23rd Nov 202212:16 pmRNSCompletion of the acquisition of Avantus
10th Nov 202212:13 pmRNSDirector/PDMR Shareholding
10th Nov 20227:00 amRNSInterim Results
12th Oct 20227:00 amRNSSecond Quarter Trading Update
11th Oct 20223:28 pmRNSDirector/PDMR Shareholding
3rd Oct 20227:06 amRNSAcquisition of Air Affairs & disposal of Space NV
12th Sep 20223:28 pmRNSDirector/PDMR Shareholding
26th Aug 202212:53 pmRNSDirector/PDMR Shareholding
10th Aug 20223:36 pmRNSDirector/PDMR Shareholding
9th Aug 20227:00 amRNSDelivering growth in the US with $45m contract win
5th Aug 20226:22 pmRNSProposed Acquisition of Avantus Federal LLC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.